Literature DB >> 10963622

Tissue-specific synthesis and oxidative metabolism of estrogens.

C R Jefcoate1, J G Liehr, R J Santen, T R Sutter, J D Yager, W Yue, S J Santner, R Tekmal, L Demers, R Pauley, F Naftolin, G Mor, L Berstein.   

Abstract

Estrogen exposure represents the major known risk factor for development of breast cancer in women and is implicated in the development of prostate cancer in men. Human breast tissue has been shown to be a site of oxidative metabolism of estrogen due to the presence of specific cytochrome P450 enzymes. The oxidative metabolism of 17beta-estradiol (E2) to E2-3,4-quinone metabolites by an E2-4-hydroxylase in breast tissue provides a rational hypothesis to explain the mammary carcinogenic effects of estrogen in women because this metabolite is directly genotoxic and can undergo redox cycling to form genotoxic reactive oxygen species. In this chapter, evidence in support of this hypothesis and of the role of P4501B1 as the 4-hydroxylase expressed in human breast tissue is reviewed. However, the plausibility of this hypothesis has been questioned on the grounds that insufficient E2 is present in breast tissue to be converted to biologically significant amounts of metabolite. This critique is based on the assumption that plasma and tissue E2 levels are concordant. However, breast cancer tissue E2 levels are 10-fold to 50-fold higher in postmenopausal women than predicted from plasma levels. Consequently, factors must be present to alter breast tissue E2 levels independently of plasma concentrations. One such factor may be the local production of E2 in breast tissue through the enzyme aromatase, and the evidence supporting the expression of aromatase in breast tissue is also reviewed in this chapter. If correct, mutations or environmental factors enhancing aromatase activity might result in high tissue concentrations of E2 that would likely be sufficient to serve as substrates for CYP1B1, given its high affinity for E2. This concept, if verified experimentally, would provide plausibility to the hypothesis that sufficient E2 may be present in tissue for formation of catechol metabolites that are estrogenic and which, upon further oxidative metabolism, form genotoxic species at levels that may contribute to estrogen carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963622     DOI: 10.1093/oxfordjournals.jncimonographs.a024248

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  56 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

2.  Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer.

Authors:  Bhupendra Singh; Nimee K Bhat; Hari K Bhat
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

3.  Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland.

Authors:  Taehyun Kim; Hoyong Park; Wei Yue; Ji-Ping Wang; Kristen A Atkins; Zhenguo Zhang; Eleanor G Rogan; Ercole L Cavalieri; Khalid S Mohammad; Sanghee Kim; Richard J Santen; Sarah E Aiyar
Journal:  Breast Cancer Res Treat       Date:  2010-12-18       Impact factor: 4.872

4.  Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women.

Authors:  Susan E Olivo-Marston; Leah E Mechanic; Steen Mollerup; Elise D Bowman; Alan T Remaley; Michele R Forman; Vidar Skaug; Yun-Ling Zheng; Aage Haugen; Curtis C Harris
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

5.  Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model.

Authors:  Nur Ozten; Lori Horton; Salamia Lasano; Maarten C Bosland
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

6.  The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention.

Authors:  Maarten C Bosland
Journal:  Rev Urol       Date:  2005

Review 7.  Estrogens and prostate cancer: etiology, mediators, prevention, and management.

Authors:  Shuk-Mei Ho; Ming-Tsung Lee; Hung-Ming Lam; Yuet-Kin Leung
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-07       Impact factor: 4.741

8.  L-selenomethionine does not protect against testosterone plus 17β-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats.

Authors:  Nur Özten; Michael Schlicht; Alan M Diamond; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2014-04-28       Impact factor: 2.900

9.  Estrogen metabolism by cytochrome P450 1B1 modulates the hypertensive effect of angiotensin II in female mice.

Authors:  Brett L Jennings; L Watson George; Ajeeth K Pingili; Nayaab S Khan; Anne M Estes; Xiao R Fang; Frank J Gonzalez; Kafait U Malik
Journal:  Hypertension       Date:  2014-04-28       Impact factor: 10.190

10.  Antiestrogen pathway (aromatase inhibitor).

Authors:  Zeruesenay Desta; Anne Nguyen; David Flockhart; Todd Skaar; Rebecca Fletcher; Richard Weinshilboum; Dorit S Berlin; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.